Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

Pfizer

Status: Completed

Conditions: Carcinoma, Renal Cell

Treatments: Drug: sunitinib malate

Study type: Observational

Funder types: Industry

Identifiers

NCT00716625

A6181176

Details and patient eligibility

About

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Full description

All the patients whom an investigator prescribes the first sunitinib malate(Sutent) should be registered.

Enrollment: 1,674 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients need to be administered sunitinib malate (Sutent) in order to be enrolled in the surveillance.

Exclusion criteria

• Patients not administered sunitinib malate (Sutent).

Trial design

1,674 participants in 1 patient group

sunitinib malate

Description:

Patients taking sunitinib malate

Treatment:

Drug: sunitinib malate